China Diabetes Cardiovascular Initiative

NCT05037058 | Unknown

• 1 other identifier: CDCV2021
• Study Type: observational
• Target: 9,600
• Locations: 0 countries
• Sites: N/A

Brief Summary

As a collaborative project between American Heart Association, Chinese Society of Cardiology, American Diabetes Association and Chinese Diabetes Society, the China Diabetes Cardiovascular Initiative aims to enhance the attention and awareness of cardiovascular health care professionals (HCPs) in the managements of cardiovascular diseases and diabetes, to reduce diabetes-related complication and minimize adverse events in patients with cardiovascular disease, and to reduce the risk of cardiovascular morbidity and mortality in diabetic patients.

Conditions

Acute Coronary Syndrome; Diabetes Mellitus

Outcome Measures

Primary Outcomes (20)

• Proportion of patients receiving dual antiplatelet therapy at arrival (within 24 hours)

  Duration of hospital stay, an expected average of 1 week

• Proportion of STEMI patients receiving fibrinolytic therapy within 30 minutes after arrival among those receiving this treatment

  Duration of hospital stay, an expected average of 1 week

• Proportion of STEMI patients receiving reperfusion therapy by PCI

  Duration of hospital stay, an expected average of 1 week

• Proportion of STEMI patients receiving primary PCI within 90 minutes after arrival among those receiving this treatment

  Duration of hospital stay, an expected average of 1 week

• Proportion of NSTE-ACS patients receiving early cardiac troponin measurement (within 6 hours of arrival)

  Duration of hospital stay, an expected average of 1 week

• Proportion of NSTE-ACS patients receiving risk stratification at admission

  Duration of hospital stay, an expected average of 1 week

• Proportion of NSTE-ACS patients receiving PCI within recommended times for patients with high or intermediate risk

  Duration of hospital stay, an expected average of 1 week

• Proportion of patients prescribed dual antiplatelet medications at discharge

  Duration of hospital stay, an expected average of 1 week

• Proportion of patients with indications prescribed a beta-blocker at discharge

  Duration of hospital stay, an expected average of 1 week

• Proportion of patients prescribed a statin at discharge

  Duration of hospital stay, an expected average of 1 week

• Proportion of patients with indications prescribed an ACE-I or ARB at discharge

  Duration of hospital stay, an expected average of 1 week

• Proportion of patients that receiving an LDL-C assessment

  Duration of hospital stay, an expected average of 1 week

• Proportion of patients with evaluation for LV systolic function by echocardiography

  Duration of hospital stay, an expected average of 1 week

• Proportion of smoking patients that receiving smoking cessation advice/counseling

  Duration of hospital stay, an expected average of 1 week

• Proportion of patients receiving fasting glucose test at least twice

  Duration of hospital stay, an expected average of 1 week

• Proportion of patients receiving HbA1C test

  Duration of hospital stay, an expected average of 1 week

• Proportion of patients prescribed a SGLT-2 inhibitor or a GLP-1 receptor agonist at discharge with cardiovascular disease benefit

  Duration of hospital stay, an expected average of 1 week

• Proportion of patients with body height and weight measured and documented

  Duration of hospital stay, an expected average of 1 week

• Proportion of patients receiving guidance on individualized dietary

  Duration of hospital stay, an expected average of 1 week

• Proportion of patients receiving guidance on individualized physical activity

  Duration of hospital stay, an expected average of 1 week

Interventions

Quality improvement activities OTHER

Quality improvement activities

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients hospitalized with acute coronary syndrome and diabetes from 40 tertiary hospitals from China.

You may qualify if:

• Patients hospitalized with acute coronary syndrome and diabetes.
• Aged at least 18 years.

You may not qualify if:

• None

Sponsors & Collaborators

• Beijing Institute of Heart, Lung and Blood Vessel Diseases: lead

MeSH Terms

Conditions

Acute Coronary Syndrome; Diabetes Mellitus

Condition Hierarchy (Ancestors)

Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Central Study Contacts

Yongchen Hao, Ph. D

CONTACT

+86(10)64456549; haoyongchen123@163.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor of Beijing Institute of Heart, Lung and Blood Vessel Diseases

Study Record Dates

• First Submitted: August 31, 2021
• First Posted: September 8, 2021
• Study Start: September 1, 2021
• Primary Completion: December 31, 2023
• Study Completion: December 31, 2023
• Last Updated: September 8, 2021

Record last verified: 2021-08